Skip to Content
Is technology key to beating breast cancer? Learn more >

Fluorouracil Pregnancy and Breastfeeding Warnings

Fluorouracil is also known as: Adrucil

Fluorouracil Pregnancy Warnings

Animal studies revealed evidence of embryolethality and teratogenicity (i.e., abortion, resorptions, delays in growth, cleft palate, skeletal defects, deformed appendages [paws and tails], micro-anophthalmos) at doses lower than the human dose of 12 mg/kg. There are no controlled data in human pregnancy. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

AU, UK: Contraindicated US: This drug should be used during pregnancy only if the benefit outweighs the risk. AU TGA pregnancy category: D US FDA pregnancy category: D Comments: -Based on its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman. -Women of childbearing potential should be advised to avoid becoming pregnant and to use an effective method of contraception during therapy with this drug and for up to 6 months after discontinuing therapy. -If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential hazard to the fetus and genetic counseling is recommended. -Men treated with this drug should be advised not to father a child during and for up to 6 months after discontinuing therapy. Advice men on conservation of sperm because of the possibility of irreversible infertility due to therapy.

See references

Fluorouracil Breastfeeding Warnings

Most experts consider breastfeeding contraindicated during maternal antineoplastic drug therapy. It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence, but the duration of abstinence is not clear.

UK: Contraindicated AU, US: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: -The effects in the nursing infant are unknown. -If this drug is used during breastfeeding, a complete blood count and differential is recommended in the infant.

See references

References for pregnancy information

  1. "Product Information. Fluorouracil (fluorouracil)." BluePoint Laboratories, Norwich, NY.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  2. "Product Information. Fluorouracil (fluorouracil)." BluePoint Laboratories, Norwich, NY.
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide